Regulation of mRNA gene expression of members of the NF-κB transcription factor gene family by angiotensin II and relaxin 2 in normal and cancer prostate cell lines.

An increasing number of researchers are focusing on the influence of local peptide hormones such as angiotensin II (Ang II) and relaxin 2 (RLN2) in the regulation of inflammation and carcinogenesis. The interaction between the renin­angiotensin system (RAS) and relaxin family peptide system (RFPS) is known to influence the proliferation, adhesion and migration of normal and cancer prostate cell lines. The aim of the present study was to evaluate changes in the expression of nuclear factor­κB subunit 1 (NFKB1), nuclear factor­κB subunit 2 (NFKB2), REL proto­oncogene nuclear factor­κB p65 subunit (REL), RELA proto­oncogene nuclear factor­κB subunit (RELA) and RELB proto­oncogene nuclear factor­κB subunit (RELB) mRNA caused by Ang II and RLN2. The members of NF­kB family are involved in many processes associated with cancer development and metastasis. Reverse transcription­quantitative polymerase chain reaction analysis identified that both peptide hormones have an influence on the relative expression of nuclear factor­κB. Following treatment with either peptide, NFKB1 expression was downregulated in all prostate cancer cell lines (LNCaP, DU­145 and PC3), but not in normal epithelial cells (PNT1A). Conversely, RELB mRNA was enhanced only in non­cancerous prostate cells. RELA expression was strongly stimulated in the most aggressive cell line, whereas REL mRNA was unchanged. In many cases, the effect was strictly dependent on the cell line and/or the type of peptide: Ang II increased expression of both RELA and REL genes in the androgen­dependent cell line while RLN2 enhanced NFKB2 and RELA mRNA in androgen­independent cells (DU­145). Further research is needed to understand the regulation of NF­κB family members by key renin­angiotensin system and RFPS peptides in prostate cancer cells; however, prostate carcinogenesis appears to be influenced by the balance between the cross­regulation of nuclear factor­κB (NF­κB) and androgen receptor pathways by Ang II and relaxin 2.

The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer.

Endometrial cancer (EC) is the most common gynecological malignancy. Alterations of angiogenic factors including angiotensin (AngII) or VEGF are observed in EC. Expression of angiotensin receptor 1 (AT1) is correlated with EC. Moreover, the expression of VEGF is up-regulated by AngII. Androgens are involved in the pathogenesis of EC. Genetic variations in androgen receptor (AR) gene may increase EC risk. This review proved strong correlation among EC, AngII, its receptors and AR, where AT influence on AR and, as a result, induce the expression of genes related to carcinogenesis.